Synchronous Thyroid and Gastric Mantle Cell Lymphoma

Main Article Content

Kmira Zahra
Rania Bouneb
Sarra Mestiri
Mohamed Mahjoub
Monia Zaier
Yosra Ben Youssef
Abderrahim Khelif


Introduction: Mantle cell lymphoma (MCL) is a distinct entity within the World Health Organization classification of lymphoid neoplasm and represents approximately 8% of lymphoma. Patients with mantle-cell lymphoma typically present with extensive disease and involvement of multiple lymph nodes as well as the spleen, bone marrow, blood, and gastrointestinal tract. MCL of the thyroid occurs exceptionally. The MCL of the stomach is also an exceptional occurrence.

Observation: We describe the case of a 58-year-old male who was diagnosed with thyroid and gastric MCL. The patient was classified into high risk group according to the Mantle Cell Lymphoma International Prognostic Index (MIPI). The R-CHOP (Rituximab, Cyclophosphamide, Adriablastine, Vincristine and Prednisone) regimen was started and complete remission was achieved after 8 courses. He currently receives a maintenance treatment with rituximab every two months.

Conclusion: This case is a combination of two rather infrequent extranodal localizations of the MCL.

Mantle cell lymphoma, thyroid, stomach, chemotherapy

Article Details

How to Cite
Zahra, K., Bouneb, R., Mestiri, S., Mahjoub, M., Zaier, M., Youssef, Y., & Khelif, A. (2016). Synchronous Thyroid and Gastric Mantle Cell Lymphoma. International Journal of Medical and Pharmaceutical Case Reports, 8(1), 1-6.
Case Study